Product Description

The first and only chimeric recombinant canine Lyme disease vaccine helps provide broad spectrum coverage against outer surface protein A (OspA), found in the tick, and contains antigens from multiple types of outer surface protein C (OspC), found in the tick and dog.

Features & Benefits

• Indication: For vaccination of healthy dogs 8 weeks of age or older as an aid in the prevention of clinical disease and subclinical arthritis associated with Borrelia burgdorferi
• Administration: 1 mL subcutaneous vaccine; dogs should be administered two doses, three weeks apart; annual revaccination recommended